date:Jul 05, 2012
d immunity.
During the past few years, companies like DuPont have learnt how to run clinical trials and prepare dossiers that will correspond to EFSA's needs and operating mode, so we can see the current lack of approvals as a temporary situation.
Darribeau spoke of an international scientific community that was testing the effects of probiotic formulations on areas such as immune and digestive health, obesity and stool transit. He said DuPont was developing a global collaborative network to g